Clinical outcomes and toxicities of pazopanib administered orally in crushed form: Case reports and review of the literature

Cancer treatment has changed dramatically with the development of oral targeted therapies. Pazopanib, an oral VEGF tyrosine kinase inhibitor, is currently approved for advanced renal cell carcinoma, advanced soft tissue sarcoma, and is being studied for various tumor types. Due to the potential of i...

Full description

Saved in:
Bibliographic Details
Published in:Journal of oncology pharmacy practice 2020-01, Vol.26 (1), p.232-235
Main Authors: Stein, Jill, Milhem, Mohammed, Vaena, Daniel
Format: Article
Language:English
Subjects:
Adult
Aged
Carcinoma, Renal Cell - drug therapy
Case crushing
Case reports
Chordoma - drug therapy
Clinical outcomes
Crushing
Enzyme inhibitors
Female
Humans
Inhibitor drugs
Kidney cancer
Kidney Neoplasms - drug therapy
Literature reviews
Oral administration
Protein Kinase Inhibitors - adverse effects
Protein Kinase Inhibitors - therapeutic use
Protein-tyrosine kinase
Pyrimidines - administration & dosage
Pyrimidines - adverse effects
Pyrimidines - therapeutic use
Renal cell carcinoma
Sarcoma
Skull Base Neoplasms - drug therapy
Soft tissue sarcoma
Sulfonamides - administration & dosage
Sulfonamides - adverse effects
Sulfonamides - therapeutic use
Targeted cancer therapy
Toxicity
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer treatment has changed dramatically with the development of oral targeted therapies. Pazopanib, an oral VEGF tyrosine kinase inhibitor, is currently approved for advanced renal cell carcinoma, advanced soft tissue sarcoma, and is being studied for various tumor types. Due to the potential of increased exposure to pazopanib when crushed, pazopanib should be given as an intact whole tablet. Thus, in patients with difficulty swallowing medications or feeding tubes, pazopanib is usually not considered to be an option. Here, we describe two cases which show the administration of crushed pazopanib was feasible and had apparent clinical activity.
ISSN:1078-1552
1477-092X
DOI:10.1177/1078155219841108